Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial

NCT07616531 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07616531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
February 28, 2030
Enrollment
118 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gout flares